Impact of bezafibrate and atorvastatin on lipoprotein subclass in patients with type III hyperlipoproteinemia: Result from a crossover study-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Impact of bezafibrate and atorvastatin on lipoprotein subclass in patients with type III hyperlipoproteinemia: Result from a crossover study

Published:2011-05 Issue:11-12 Volume:412 Page:1068-1075
ISSN:0009-8981
Container-title:Clinica Chimica Acta
language:en
Short-container-title:Clinica Chimica Acta

Author:

Kawashiri Masa-aki,Kobayashi Junji,Nohara Atsushi,Noguchi Tohru,Tada Hayato,Nakanishi Chiaki,Inazu Akihiro,Mabuchi Hiroshi,Yamagishi Masakazu

Publisher

Elsevier BV

Subject

Biochemistry (medical),Clinical Biochemistry,Biochemistry,General Medicine

Reference28 articles.

1. Type III hyperlipoproteinemia exaggerated by Sheehan's syndrome with advanced systemic atherosclerosis: a 28-year clinical course;Kawashiri;Circ J,2005

2. Pathogenesis of type III hyperlipoproteinemia (dysbetalipoproteinemia). Questions, quandaries, and paradoxes;Mahley;J Lipid Res,1999

3. Apolipoprotein E and familial dysbetalipoproteinemia: clinical, biochemical, and genetic aspects;Smelt;Semin Vasc Med,2004

4. Remnant lipoprotein metabolism: key pathways involving cell-surface heparan sulfate proteoglycans and apolipoprotein E;Mahley;J Lipid Res,1999

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Genomics of hypertriglyceridemia;Advances in Clinical Chemistry;2020

2. Exploration and Development of PPAR Modulators in Health and Disease: An Update of Clinical Evidence;International Journal of Molecular Sciences;2019-10-11

3. Effect of adding bezafibrate to standard lipid-lowering therapy on post-fat load lipid levels in patients with familial dysbetalipoproteinemia. A randomized placebo-controlled crossover trial;Journal of Lipid Research;2017-11

4. Familial dysbetalipoproteinemia;Current Opinion in Endocrinology & Diabetes and Obesity;2017-04

5. Type III Hyperlipoproteinemia: Still Worth Considering?;Progress in Cardiovascular Diseases;2016-09

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3